Health Economics›Gastric cancer›Adjuvant therapy

Adjuvant therapy

Gastric cancer · 18 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Doxifluridine and Mitomycin Variant #01 Partial	—	R 4 311	90d	—	—	—	—	—
Carboplatin and Docetaxel (DCb) Variant #01	—	R 3 300	21d	—	55.3 mo	—	—	—
Fluorouracil and Mitomycin Variant #01	—	R 3 241	42d	—	—	—	—	—
FAM Variant #01	—	R 3 143	56d	—	—	—	—	—
FP/Capecitabine and RT Variant #01	—	R 3 022	63d	—	—	—	—	—
CapeOx Variant #01	—	R 2 384	21d	—	—	—	—	1
Docetaxel and S-1 Variant #01 Partial	—	R 1 931	21d	—	—	—	—	1
FULV and RT Variant #07	—	R 1 616	70d	—	36.0 mo	—	—	1
FULV Variant #01	—	R 1 466	35d	—	~7.5 mo	—	—	1
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 386	21d	~5.4 mo	~11.1 mo	~8	~R 11 092 PFS proxy · indirect	9
SOX Variant #01 Partial	—	R 1 075	21d	~5.6 mo	—	~9	~R 9 677 PFS proxy · indirect	2
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	~10.8 mo	—	—	2
FA Variant #01	—	R 587	21d	—	—	—	—	—
Cisplatin and S-1 Variant #01 Partial	—	R 375	28d	~5.5 mo	~14.1 mo	~6	~R 2 250 PFS proxy · indirect	10
FULV/FULV and RT Partial	—	—	—	—	—	—	—	—
UFT monotherapy Variant #04 Partial	—	—	28d	—	—	—	—	1
Observation Partial	—	—	—	—	35.9 mo	—	—	7
S-1 monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	2

18 of 18 regimens shown